Improved Diagnostic Multimodal Biomarkers for Alzheimer’s Disease and Mild Cognitive Impairment

The early diagnosis of Alzheimer’s disease (AD) and mild cognitive impairment (MCI) is very important for treatment research and patient care purposes. Few biomarkers are currently considered in clinical settings, and their use is still optional. The objective of this work was to determine whether m...

Full description

Bibliographic Details
Main Authors: Antonio Martínez-Torteya, Víctor Treviño, José G. Tamez-Peña
Format: Article
Language:English
Published: Hindawi Limited 2015-01-01
Series:BioMed Research International
Online Access:http://dx.doi.org/10.1155/2015/961314
id doaj-e46ad4f6b5044b18a069b763ffdebf71
record_format Article
spelling doaj-e46ad4f6b5044b18a069b763ffdebf712020-11-24T22:59:59ZengHindawi LimitedBioMed Research International2314-61332314-61412015-01-01201510.1155/2015/961314961314Improved Diagnostic Multimodal Biomarkers for Alzheimer’s Disease and Mild Cognitive ImpairmentAntonio Martínez-Torteya0Víctor Treviño1José G. Tamez-Peña2Cátedra de Bioinformática, Tecnológico de Monterrey, 64849 Monterrey, NL, MexicoCátedra de Bioinformática, Tecnológico de Monterrey, 64849 Monterrey, NL, MexicoCátedra de Bioinformática, Tecnológico de Monterrey, 64849 Monterrey, NL, MexicoThe early diagnosis of Alzheimer’s disease (AD) and mild cognitive impairment (MCI) is very important for treatment research and patient care purposes. Few biomarkers are currently considered in clinical settings, and their use is still optional. The objective of this work was to determine whether multimodal and nonpreviously AD associated features could improve the classification accuracy between AD, MCI, and healthy controls, which may impact future AD biomarkers. For this, Alzheimer’s Disease Neuroimaging Initiative database was mined for case-control candidates. At least 652 baseline features extracted from MRI and PET analyses, biological samples, and clinical data up to February 2014 were used. A feature selection methodology that includes a genetic algorithm search coupled to a logistic regression classifier and forward and backward selection strategies was used to explore combinations of features. This generated diagnostic models with sizes ranging from 3 to 8, including well documented AD biomarkers, as well as unexplored image, biochemical, and clinical features. Accuracies of 0.85, 0.79, and 0.80 were achieved for HC-AD, HC-MCI, and MCI-AD classifications, respectively, when evaluated using a blind test set. In conclusion, a set of features provided additional and independent information to well-established AD biomarkers, aiding in the classification of MCI and AD.http://dx.doi.org/10.1155/2015/961314
collection DOAJ
language English
format Article
sources DOAJ
author Antonio Martínez-Torteya
Víctor Treviño
José G. Tamez-Peña
spellingShingle Antonio Martínez-Torteya
Víctor Treviño
José G. Tamez-Peña
Improved Diagnostic Multimodal Biomarkers for Alzheimer’s Disease and Mild Cognitive Impairment
BioMed Research International
author_facet Antonio Martínez-Torteya
Víctor Treviño
José G. Tamez-Peña
author_sort Antonio Martínez-Torteya
title Improved Diagnostic Multimodal Biomarkers for Alzheimer’s Disease and Mild Cognitive Impairment
title_short Improved Diagnostic Multimodal Biomarkers for Alzheimer’s Disease and Mild Cognitive Impairment
title_full Improved Diagnostic Multimodal Biomarkers for Alzheimer’s Disease and Mild Cognitive Impairment
title_fullStr Improved Diagnostic Multimodal Biomarkers for Alzheimer’s Disease and Mild Cognitive Impairment
title_full_unstemmed Improved Diagnostic Multimodal Biomarkers for Alzheimer’s Disease and Mild Cognitive Impairment
title_sort improved diagnostic multimodal biomarkers for alzheimer’s disease and mild cognitive impairment
publisher Hindawi Limited
series BioMed Research International
issn 2314-6133
2314-6141
publishDate 2015-01-01
description The early diagnosis of Alzheimer’s disease (AD) and mild cognitive impairment (MCI) is very important for treatment research and patient care purposes. Few biomarkers are currently considered in clinical settings, and their use is still optional. The objective of this work was to determine whether multimodal and nonpreviously AD associated features could improve the classification accuracy between AD, MCI, and healthy controls, which may impact future AD biomarkers. For this, Alzheimer’s Disease Neuroimaging Initiative database was mined for case-control candidates. At least 652 baseline features extracted from MRI and PET analyses, biological samples, and clinical data up to February 2014 were used. A feature selection methodology that includes a genetic algorithm search coupled to a logistic regression classifier and forward and backward selection strategies was used to explore combinations of features. This generated diagnostic models with sizes ranging from 3 to 8, including well documented AD biomarkers, as well as unexplored image, biochemical, and clinical features. Accuracies of 0.85, 0.79, and 0.80 were achieved for HC-AD, HC-MCI, and MCI-AD classifications, respectively, when evaluated using a blind test set. In conclusion, a set of features provided additional and independent information to well-established AD biomarkers, aiding in the classification of MCI and AD.
url http://dx.doi.org/10.1155/2015/961314
work_keys_str_mv AT antoniomartineztorteya improveddiagnosticmultimodalbiomarkersforalzheimersdiseaseandmildcognitiveimpairment
AT victortrevino improveddiagnosticmultimodalbiomarkersforalzheimersdiseaseandmildcognitiveimpairment
AT josegtamezpena improveddiagnosticmultimodalbiomarkersforalzheimersdiseaseandmildcognitiveimpairment
_version_ 1725643026814992384